Form 4: Vera Therapeutics COO Acquires Shares and Options

David Lee Johnson, Chief Operating Officer of Vera Therapeutics, reports acquisition of shares and stock options.

Summary

• On February 18, 2025, David Lee Johnson, the Chief Operating Officer of Vera Therapeutics, acquired 26,900 shares of Class A Common Stock underlying restricted stock units (RSUs) under the company's 2021 Equity Incentive Plan.
• These RSUs vest in equal installments on February 20 of 2026, 2027, 2028, and 2029, contingent upon continuous service.
• Johnson also acquired options to purchase 53,800 shares of Class A Common Stock at an exercise price of $29.18.
• These options vest monthly, starting March 18, 2025, with 1/48th of the shares vesting each month, also subject to continuous service, and expire on February 17, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The filing reflects standard executive compensation practices and insider confidence, but doesn't contain information that would drastically alter investor perception.

Positives

• The acquisition of shares and options by the COO signals confidence in the company's future performance.

Future Outlook

The vesting schedules for both the RSUs and stock options are contingent upon the Reporting Person's continuous service, suggesting an expectation of continued employment and contribution to the company.

Industry Context

This filing is a routine disclosure related to executive compensation and equity ownership, common in publicly traded companies. It provides transparency to investors regarding the alignment of management's interests with those of shareholders.

Comparison to Industry Standards

• Equity compensation is a standard practice in the biotechnology industry to attract and retain talent.
• Vesting schedules, such as the ones described in the document, are typical for stock options and RSUs.
• Comparing the size of the equity grants to those of executives at comparable biotech companies (e.g., those with similar market capitalization and stage of development) would provide a benchmark for assessing the competitiveness of Vera Therapeutics' compensation practices.

Stakeholder Impact

• The acquisition of shares and options by the COO aligns his interests with those of shareholders, potentially leading to decisions that benefit the company's long-term value.

Key Dates